Enovis Corporation (ENOV) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

66OpportunityDD: Jul 08, 2026Analyst: 66

paidPrice at analysis date

USD 25.5 (08/07/2026)

domainMkt cap

$1.47B

pie_chartShares

57.56M

candlestick_chart52W

$19.14-$36.82

trending_downShort interest

15.72%

INFONYSEHealth Care7802 employeesFounded 2022

Verdict: Moderately Attractive

Deep-value setup: forward P/E ~6x and P/B ~0.9x on a real $2.3B revenue medtech with expanding margins (Q1 26 GM 62%, adj EBITDA +19% y/y) and reaffirmed FY26 guidance. Balance sheet is the swing factor — $1.38B net debt, 3.3x leverage on FY26E EBITDA, and heavy 15.7% short interest anchor sentiment. Value is real if margin expansion + deleveraging execute; base upside ~+25%, floor near tangible book cushions the downside.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-08

Enovis Corporation (ENOV)

Medical Devices / Orthopedics · NYSE · Dallas, TX

"Cheap on multiples, but leverage and FCF conversion cap the re-rating pace."

Fwd P/E ~6x Net debt $1.38B Q1 EPS beat +10% Short int. 15.7% GM 62%

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — EV/EBITDA multiple (FY26E)

Fair value base case

USD 32.0

Range: USD 18.0-USD 46.0

Price at analysis date: USD 25.5 (08/07/2026)

Base upside/downside: +25%

EV/EBITDA fw as primary method (profitable medtech with stable multiples); DCF as cross-check (±6%). Implied multiple 7.5x sits between peer median 10x and distressed 5.5x, reflecting deleveraging trajectory not yet earned. Scenario weights (Base 50 / Bull 20 / Bear 30) reflect [VALUE] factor tilt: solid mean-reversion probability, tail risk on execution. Prob-weighted FV ≈ $30.4. ⚠️ Not investment advice.

Component	Assumption	USD/share
Reconstructive EV	FY26E EBITDA share ~$260M × 8.5x (peer-adj: +1.0x growth premium, -1.5x leverage) → $2.21B EV / 57.56M	+38.40
Prevention & Recovery EV	FY26E EBITDA share ~$170M × 6.0x (peer-adj: -4.0x for negative organic, mature CGM/bracing) → $1.02B EV / 57.56M	+17.72
Net debt	($33M cash − $1,410M total debt) / 57.56M shares	−23.93
ARVIS option value	25% probability × $150M NPV (surgical navigation platform ramp) / 57.56M	+0.65
Litigation / contingent reserve	Modeled $50M reserve (LimFlow acquisition earn-out + product liability tail) / 57.56M	−0.87
FV base case	Exact sum of rows above	≈ $31.97

Bull

$42–46

Probability: 20%

Recon organic growth accelerates >7% via ARVIS + hip launches, FY26 EBITDA above guidance ($440M+), P&R inflects positive, leverage falls below 2.5x by year-end 2027. Multiple expands to 9x → $45+.

Base

$28–34

Probability: 50%

FY26 guidance met in mid-range, Recon ~5% organic, P&R low single-digit growth. EBITDA $425-435M, FCF ramp to $80-120M. Multiple holds at 7.5x, deleveraging visible → base ~$32.

Bear

$16–22

Probability: 30%

Q2/Q3 misses on P&R weakness, EBITDA slips below $410M, further goodwill impairment. Multiple compresses to 5.5x, refinancing risk if rates stay elevated. Floor near tangible book (~$18) provides some anchor but not a hard floor.

Methodology: EV/EBITDA fw as primary method (profitable medtech with stable multiples); DCF as cross-check (±6%). Implied multiple 7.5x sits between peer median 10x and distressed 5.5x, reflecting deleveraging trajectory not yet earned. Scenario weights (Base 50 / Bull 20 / Bear 30) reflect [VALUE] factor tilt: solid mean-reversion probability, tail risk on execution. Prob-weighted FV ≈ $30.4. ⚠️ Not investment advice. Not investment advice.

⚠️ Methodology note: ENOV screened as [VALUE] under the factor mode (forward P/E < 15, Q1 EPS beat > 5%, deep discount to peer multiples). Classification drives the scenario weighting, not the fair value: the FV is derived independently from peer-median EV/EBITDA fw with numeric adjustments for leverage and FCF quality.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

15.7%

9.05M shares short vs 56.59M float, days-to-cover 8.4. High — reflects skepticism on debt paydown pace and P&R organic growth. Squeeze risk asymmetric on upside beats.

🟡 Share dilution (1Y)

+2.49%

From 56.16M to 57.56M shares. Primarily stock-based comp; no equity raise. QoQ dilution +0.18% — pace decelerating.

🔴 Buyback

No active repurchase program. Capital priority is debt paydown ($1.41B total, target <3x leverage). Buyback yield: -2.49% (net issuance).

Short Interest — context

ENOV — 15.7%

15.7%

SI at 15.7% is in the "high" band (15-25%). Signals structural skepticism from hedge funds on the deleveraging story and P&R turnaround. A clean Q2 (Aug 6) with margin follow-through would compress shorts; a miss adds fuel to the bear case. No confirmed insider selling >$500K in last 12 months per Form 4 filings.

$Financial analysis — FY2026 guidance

Revenue TTM

$2.28B

+6.0% YoY

Adj. EBITDA TTM

$372M

margin 16.3%

Net debt

$1.38B

3.3x FY26E EBITDA

FCF TTM

$36M

conversion ~10%

Item	FY2023	FY2024	FY2025	TTM Q1'26	Guidance FY2026
Revenue ($M)	1,708	2,113	2,253	2,283	2,310–2,370
Adj. EBITDA ($M)	270	355	380	388	425–435
Adj. EBITDA margin	15.8%	16.8%	16.9%	17.0%	~18.3%
Net income (GAAP, $M)	−41	−820	−1,180	−1,142	n/d (goodwill tail)
Adj. EPS ($)	2.72	3.15	3.35	3.43	3.52–3.73
Free cash flow ($M)	15	25	32	36	~80–120
Net debt ($M)	1,240	1,510	1,420	1,377	<1,300

Note: FY24-FY25 heavy GAAP losses driven by ~$800M goodwill impairment tied to Lima and other legacy acquisitions. Adjusted metrics reflect underlying business economics. FY26 guidance reaffirmed at Q1 26 print (May 7, 2026).

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	559	566	541	587	589
Gross margin %	60.5%	60.8%	60.4%	61.5%	62.0%
Adj. EBITDA ($M)	87.1	92.5	85.0	115.4	103.6
End-of-period cash ($M)	62	55	48	42	33

Financial position and sustainability

Deleveraging trajectory

3.3x → 2.5x by '27E

Q1 26 Adj EPS vs consensus

$0.89 vs $0.81 (+10%)

Revenue growth (organic FY26E)

4–6%

FCF conversion vs peer avg

10% vs peer ~60%

account_tree

Business model — Innovation-led orthopedic medtech

Two-segment medtech with recon focus

Enovis spun off from Colfax in 2022 to become a pure-play medical technology company. Operates two segments: Reconstructive (Recon), covering hip/knee/extremities implants + ARVIS surgical navigation, and Prevention & Recovery (P&R), covering orthopedic bracing (DonJoy), cold therapy, bone growth stimulation, and rehabilitation devices. Recon is the growth engine (6% organic Q1 26); P&R is the cash cow but with soft demand (1% organic). ~7,800 employees, dual-segment model targeting orthopedic specialists, surgeons, and physical therapists globally.

Reconstructive (Recon) ~$1,300–1,340M FY26E (~57% rev) 🟢 ramping Hip, knee, shoulder, foot & ankle implants + ARVIS surgical navigation platform. Growth via extremities + international recon; GM >70%; main risk is competitive pressure vs Stryker/Globus/ZBH. Prevention & Recovery (P&R) ~$1,010–1,030M FY26E (~43% rev) 🟡 stabilizing DonJoy bracing, cold therapy, bone stim, rehab devices. Mature category, +1% organic Q1 26. GM ~55%; principal risk is share loss to private-label and DME reimbursement pressure. ARVIS Platform (option) ~$30–50M FY26E (~2% rev) 🟢 early ramp Surgical navigation platform for hip/knee replacement, AR-guided. Early commercial rollout; potential platform value $150M if capture rate hits 5% of Recon procedures by 2028. High optionality, execution binary.

gavel

Legal, regulatory and risk analysis

Leverage / refinancing risk

High

$1.41B total debt, 3.3x FY26E EBITDA. Interest coverage 0.93x (GAAP) — extremely tight. Nearest maturity 2028. If rates stay elevated and FCF conversion doesn't ramp, refinancing spreads widen materially.

Goodwill impairment tail

High

~$800M cumulative impairments in FY24-FY25 tied to Lima and legacy acquisitions. Altman Z-Score 0.74 signals model-driven bankruptcy risk (though driven by non-cash writedowns, not economic distress). Further impairments possible if Recon growth stalls.

P&R organic weakness

Moderate

+1% organic Q1 26 vs +6% in Recon. Bracing category mature with private-label pressure. If P&R turns negative organic, mix shifts hurt margin arithmetic and consensus haircuts follow.

Short interest overhang

Moderate

15.7% SI on float, 8.4 days-to-cover. Structural skeptics on the deleveraging story. Two-way risk: squeeze on a Q2 beat, but persistent overhang caps rallies otherwise.

Competitive pressure Recon

Moderate

Stryker, Zimmer Biomet, Globus (post-Nuvasive) all dominant in large-joint recon. ENOV competes on extremities and ARVIS differentiation; loss of share = FV base case at risk.

Regulatory / product liability

Low

FDA baseline for orthopedic devices. No open Class III recalls. Product liability tail modeled ~$50M reserve. No active class action against management as of 2026-07.

Margin expansion executing

Positive

GM expanded from 60.5% Q1 25 to 62.0% Q1 26 — solid mix + inventory step-up tailwind. Adj EBITDA +19% y/y confirms operating leverage. Base case rests on this trend holding.

Deep valuation discount

Positive

Fwd P/E ~6x, P/B 0.88x, EV/EBITDA fw 6.2x — all near book-value floor and ~40% below peer median. Analyst consensus $42.30 (Strong Buy) 66% above current. Margin of safety is real if base thesis holds.

article

SWOT analysis

Strengths

+Real $2.3B revenue medtech, gross margin 62%, adj EBITDA margin expanding to ~17%.
+Q1 26 EPS beat +10% (adj $0.89 vs $0.81), FY26 guidance reaffirmed.
+Deep-value multiples: fwd P/E ~6x, P/B 0.88x, EV/EBITDA fw 6.2x vs peer 10x.
+Recon organic +6%, ARVIS platform ramping, extremities international traction.

Weaknesses

−Net debt $1.38B, 3.3x FY26E EBITDA — highest leverage in peer group.
−FCF conversion only ~10% (peer ~60%+); high capex + interest burden.
−$800M cumulative goodwill impairments FY24-FY25; Altman Z 0.74 red flag.
−P&R segment growing +1% organic — mature category with private-label pressure.

Opportunities

→Multiple re-rating: closing the ~40% peer discount = +$8-12/sh upside.
→ARVIS platform commercialization + hip/knee launches drive Recon >7% organic.
→Deleveraging to <2.5x by 2027 removes overhang, unlocks buybacks or M&A.
→Orthopedic market secular tailwind (aging demographics, ASC channel shift).

Threats

!Stryker/Globus/Zimmer competitive pressure in large-joint recon.
!Refinancing risk if rates stay elevated + FCF ramp slower than guidance.
!Short-seller pressure (SI 15.7%) — Q2 miss adds fuel to bear case.
!Further goodwill impairment if any BU stalls / management guidance credibility eroded.

article

Summary by assessment area

🟡 Financial risk — Moderate/High

Leverage 3.3x, interest coverage 0.93x (GAAP).
FCF conversion 10% — critical to raise to 30%+ by FY27.
Book value cushion $25.66/sh close to current price.

🔵 Business risk — Moderate

Recon growth solid; P&R mature/soft.
ARVIS optionality genuine but early.
Competitive pressure from larger peers persistent.

🟢 Valuation risk — Attractive

Fwd P/E ~6x, P/B 0.88x, EV/EBITDA fw 6.2x.
~40% discount to peer median EV/EBITDA fw.
Analyst consensus $42.30 (+66% upside).

{ "verdict_label": {"it": "Giudizio: Moderatamente Attraente", "en": "Verdict: Moderately Attractive"}, "verdict_text": {"it": "Enovis è un deep-value medtech (P/E fw ~6x, P/B 0.9x) su ricavi reali $2.3B con margini in espansione, ma leva 3.3x e FCF conversion 10% frenano il re-rating. Base upside +25%, floor tangible book.", "en": "Enovis is a deep-value medtech (fwd P/E ~6x, P/B 0.9x) on real $2.3B revenue with expanding margins, but 3.3x leverage and 10% FCF conversion cap the re-rating. Base upside +25%, floor near tangible book."}, "bull_points": [ {"it": "Multipli forward P/E 6x, EV/EBITDA fw 6.2x — ~40% sotto mediana peer medtech.", "en": "Forward P/E 6x, EV/EBITDA fw 6.2x — ~40% below medtech peer median."}, {"it": "Q1 26 EPS beat +10%, guidance FY26 riconfermata, margini in espansione a ~17%.", "en": "Q1 26 EPS beat +10%, FY26 guidance reaffirmed, margins expanding to ~17%."}, {"it": "Consensus analisti $42.30 (Strong Buy, 11 analisti) = +66% dal prezzo corrente.", "en": "Analyst consensus $42.30 (Strong Buy, 11 analysts) = +66% from current price."} ], "bear_points": [ {"it": "Debito netto $1.38B, leva 3.3x FY26E EBITDA — la più alta del peer group.", "en": "Net debt $1.38B, 3.3x FY26E EBITDA leverage — highest in peer group."}, {"it": "FCF conversion solo 10% vs peer 60%+; refinancing risk se tassi restano alti.", "en": "FCF conversion only 10% vs peer 60%+; refinancing risk if rates stay elevated."}, {"it": "P&R organic +1% Q1 26 — segmento maturo con pressione private-label.", "en": "P&R organic +1% Q1 26 — mature segment with private-label pressure."} ], "risks": [ {"it": "Short interest 15.7% — overhang strutturale sulla deleveraging story.", "en": "Short interest 15.7% — structural overhang on the deleveraging story."}, {"it": "Goodwill impairments $800M FY24-25; Altman Z 0.74 = red flag modellistico.", "en": "$800M goodwill impairments FY24-25; Altman Z 0.74 = model-based red flag."}, {"it": "Q2 26 earnings 6 agosto = catalizzatore binario, miss riattiva scenario bear.", "en": "Q2 26 earnings Aug 6 = binary catalyst, a miss reactivates the bear scenario."} ] }

Sources & Disclaimer

Sources: Company press releases (Q1 2026 earnings 2026-05-07, FY25 10-K), stockanalysis.com (statistics + price 2026-07-07), Simply Wall St (peer screener 2026-04-22), TheFly (analyst updates July 2026), SEC EDGAR, Yahoo Finance. Market data — last verified close 2026-07-07: ENOV ~$25.52, market cap ~$1.47B, 52W range $19.14–$36.82, 57.56M shares outstanding. Short interest 15.72%. Analyst consensus target $42.30 (Strong Buy, 11 analysts, updated after Evercore ISI cut PT to $32 on 2026-07-07). This document is for informational purposes only and does not constitute financial or investment advice.